v3.26.1
Segment Information - Schedule of Segment Expenses and Segment Operating Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Total general and administrative $ 6,949   $ 9,070   $ 13,823 $ 18,527
Stock based compensation 3,381   4,667   7,110 11,618
Net loss (32,933) $ (45,440) (37,161) $ (34,272) (78,373) (71,433)
Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1] 26,389   29,856   65,599 56,000
Total general and administrative [2] 5,329   6,822   10,398 12,768
Stock based compensation 3,381   4,667   7,110 11,618
Other segment items [3] (2,166)   (4,184)   (4,734) (8,953)
Net loss (32,933)   (37,161)   (78,373) (71,433)
HCV external costs | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1],[4] 17,924   24,285   47,263 41,869
HEV external costs | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1],[4] 2,910   0   6,917 0
COVID-19 external costs | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1],[4] 0   (78)   0 1,156
Early stage discovery external costs | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1],[4]     265   0 596
Compensation and related expenses | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1] 4,668   4,419   9,571 10,456
Total general and administrative [2] 2,314   2,212   4,692 4,890
Consulting and professional fees | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1] 502   568   1,069 1,087
Total general and administrative [2] 2,670   4,185   5,030 7,124
Other research and development expenses | Operating Segment            
Segment Reporting Information [Line Items]            
Total research and development expense [1] 385   397   779 836
Other general and administrative | Operating Segment            
Segment Reporting Information [Line Items]            
Total general and administrative [2] $ 345   $ 425   $ 676 $ 754
[1]

(1)Research and development expense for the three months ended June 30, 2026 and 2025 excludes stock-based compensation of $1,761 and $2,419, respectively. Research and development expense for the six months ended June 30, 2026 and 2025 excludes stock-based compensation of $3,685 and $5,859, respectively.

[2]

(3)General and administrative expense for the three months ended June 30, 2026 and 2025 excludes stock-based compensation of $1,620 and $2,248, respectively. General and administrative expense for the six months ended June 30, 2026 and 2025 excludes stock-based compensation of $3,425 and $5,759, respectively.

[3]

(4)Other segment items include interest income and other, net and income tax expense.

[4]

(2)External costs consist primarily of costs associated with preclinical, clinical and manufacturing related activities.